Marvell Technology (MRVL) has lost about 30% of its value in five days, to $170.34, in the week it announced an all-stock deal for Lumentum on November 2, 2026. The stock sits below its 40-week average, and the balance of evidence for the next two to six weeks leans negative with high conviction. Sellers have capped rallies near $175, and the shares are lagging both the market and the chip sector.
Why it matters
On November 2, Marvell filed an 8-K announcing a definitive agreement to acquire Lumentum. Lumentum holders receive 4.500 Marvell shares for each of their shares, which implies an enterprise value of $115 billion and a 23.9% premium. The stated aim is to become a leader in AI connectivity. A second filing the same day disclosed the material agreement behind the deal. The scale is the point: Marvell's own market value is about $153 billion, so it is paying with a very large block of new stock.
The shares had already fallen before this week. They peaked at $287.01 on October 6 and are now 40.7% below that close. Most of the one-month decline of 37.5% has come in the last five days. Today the stock slipped 0.62% on volume 24.4% above its 20-day average, while the chip sector bounced 2.41%. The filings give the terms but not the market's reasoning. The size of the drop is consistent with investors objecting to the price and dilution of an all-stock purchase, but nothing in the news file states that, so it is an inference.
The five-day numbers show how much of the fall belongs to the stock itself. The S&P 500 ETF (SPY) lost 2.06% and the semiconductor ETF (SOXX) lost 9.43%. MRVL lost 30.15%, which is 20.7 points worse than its sector. The market explains little of the move. The sector explains some of it. The remaining two-thirds or so is specific to Marvell.
No published debate on the deal was available, so the two sides can only be drawn from the numbers. The constructive side is the analyst community: 41 analysts rate the stock a strong buy, with a mean price target of $321.87 and a range of $175 to $450. The shares trade 47.1% below that mean. The skeptical side is the price itself, which has erased a good part of a year in which the stock was still up 100.2% year to date. The lowest target, $175, sits just above the current price, and targets set before the second filing may not reflect the deal. A gap this wide usually closes through lower targets, a higher price, or both.
What the evidence says
On the long term, the thesis is damaged rather than broken. The stock is below its 40-week average, so the long-term trend is down. It is also below its 50-day average ($240.12) and its 200-day average ($184.10), which means the multi-month uptrend has given way. Yet the shares are still 131% above the 52-week low of $73.73 and up 100.2% this year. This looks like the early phase of a large correction in a stock that ran hard, not a return to the lows.
For the next two to six weeks the balance of evidence leans negative, and conviction is high at 3 of 4. The daily trend runs with the weekly downtrend. MRVL has also lagged the S&P 500 by 27.8% and SOXX by 19.4% over 50 days, so the weakness is not just a market or sector story. Even when the chip group bounced today, MRVL did not follow.
The strongest case against this reading is that the stock is stretched. Its 14-day RSI is 27.31, which is oversold, and it trades 47.1% below the mean analyst target. Sharp drops like this often bounce. That bounce is why conviction is not at the maximum, but oversold conditions can persist in a downtrend, and a rally would first have to clear the $175 area where sellers have appeared before.
Levels that matter
The structure stays negative while the stock is below $175.0, a round number where sellers have shown up on rallies. Above it, the 200-day average at $184.10 and the round $200.0 are the next obstacles. The downtrend would end only above $240.12, the 50-day average, which is also the level where the weekly picture changes.
The downside breakout level is a daily close below $150.0, a round number and the nearest support. From there the mapped targets are $94.62 and $85.25, which give 1.9 to 1 and 2.2 to 1 against a stop at $179.57 (the $175 round level plus a quarter of the 14-day ATR of $18.30). The math does not reach 3 to 1. It would take a tighter stop, such as a failed bounce that turns back well below $175, or a target below the mapped levels, to lift the ratio. A close back above $179.57 would show that the breakdown has failed.
What would change the picture
The rule is a weekly close above $240.12, the 50-day average. That is far above the current price, and it would put the stock back above the level that has acted as a ceiling. The non-price fact that could drive it is evidence that the Lumentum deal makes strategic sense, such as better deal terms or earnings guidance showing that AI connectivity demand supports the combined company. Without something like that, a recovery of that size has little to build on.
What to watch
- Earnings, December 1, 2026: the number that matters is forward revenue guidance, because it shows whether AI demand is strong enough to justify the deal.
- Sector: SOXX is down 21.4% over a month and moves the stock before its own news. A stock that keeps lagging a bouncing sector is a weak sign.
- Valuation: the mean target of $321.87 is 47.1% above the price, and the lowest of 41 targets is $175. Target cuts after the deal would show whether analysts are narrowing that gap.